<SEC-DOCUMENT>0001213900-22-018307.txt : 20220406
<SEC-HEADER>0001213900-22-018307.hdr.sgml : 20220406
<ACCEPTANCE-DATETIME>20220406081108
ACCESSION NUMBER:		0001213900-22-018307
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20220406
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20220406
DATE AS OF CHANGE:		20220406

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Citius Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001506251
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				273425913
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38174
		FILM NUMBER:		22809425

	BUSINESS ADDRESS:	
		STREET 1:		11 COMMERCE DRIVE
		STREET 2:		1ST FLOOR
		CITY:			CRANFORD
		STATE:			NJ
		ZIP:			07016
		BUSINESS PHONE:		(908) 967-6676

	MAIL ADDRESS:	
		STREET 1:		11 COMMERCE DRIVE
		STREET 2:		1ST FLOOR
		CITY:			CRANFORD
		STATE:			NJ
		ZIP:			07016

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Trail One, Inc.
		DATE OF NAME CHANGE:	20110314

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TrailOne, Inc.
		DATE OF NAME CHANGE:	20101119
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ea157980-8k_citius.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:CTXR="http://citiuspharmaceuticals.com/20220406">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02A_US%2DGAAP%2D2021 -->
<!-- Field: Set; Name: xdx; ID: xdx_03C_CTXR_citiuspharmaceuticals.com_20220406 -->
<!-- Field: Set; Name: xdx; ID: xdx_042_20220406_20220406 -->
<!-- Field: Set; Name: xdx; ID: xdx_055_edei%2D%2DEntityCentralIndexKey_0001506251 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2022-04-06to2022-04-06" name="dei:EntityCentralIndexKey">0001506251</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-04-06to2022-04-06" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="ctxr-20220406.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2022-04-06to2022-04-06">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506251</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-06</xbrli:startDate>
        <xbrli:endDate>2022-04-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-062022-04-06_custom_CommonStock0.001ParValueMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506251</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CTXR:CommonStock0.001ParValueMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-06</xbrli:startDate>
        <xbrli:endDate>2022-04-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-062022-04-06_custom_WarrantsToPurchaseCommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506251</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CTXR:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-06</xbrli:startDate>
        <xbrli:endDate>2022-04-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">UNITED STATES</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">SECURITIES AND EXCHANGE COMMISSION</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">Washington, D.C. 20549</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">__________________</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>FORM <span id="xdx_90B_edei--DocumentType_c20220406__20220406_zZk3lEOxgRfg"><ix:nonNumeric contextRef="From2022-04-06to2022-04-06" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">__________________</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">CURRENT REPORT</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">Pursuant to Section 13 or 15(d) of</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">the Securities Exchange Act of 1934</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">Date of Report (Date of earliest event reported) <span style="text-decoration: underline"><span id="xdx_90F_edei--DocumentPeriodEndDate_c20220406__20220406_ziT0590fweWl"><ix:nonNumeric contextRef="From2022-04-06to2022-04-06" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">April
6, 2022</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">__________________</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b><span style="text-decoration: underline"><span id="xdx_901_edei--EntityRegistrantName_c20220406__20220406_zjbSYoAw5TV3"><ix:nonNumeric contextRef="From2022-04-06to2022-04-06" name="dei:EntityRegistrantName">Citius Pharmaceuticals, Inc.</ix:nonNumeric></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">(Exact name of registrant as specified in its charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">__________________</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="text-decoration: underline"><span id="xdx_902_edei--EntityIncorporationStateCountryCode_c20220406__20220406_zgMI6eB96BO"><ix:nonNumeric contextRef="From2022-04-06to2022-04-06" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Nevada</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">(State or other jurisdiction of incorporation)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1pt solid; text-align: center; width: 40%"><span id="xdx_900_edei--EntityFileNumber_c20220406__20220406_zimcwTJyIlH1"><ix:nonNumeric contextRef="From2022-04-06to2022-04-06" name="dei:EntityFileNumber">333-206903</ix:nonNumeric></span></td>
    <td style="text-align: center; width: 20%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center; width: 40%">&#160;<span id="xdx_90B_edei--EntityTaxIdentificationNumber_c20220406__20220406_zCLj3zMqQ3l"><ix:nonNumeric contextRef="From2022-04-06to2022-04-06" name="dei:EntityTaxIdentificationNumber">27-3425913</ix:nonNumeric></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">(Commission File Number)</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;(IRS Employer Identification No.)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="text-decoration: underline"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 30%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center; width: 40%"><span id="xdx_90B_edei--EntityAddressAddressLine1_c20220406__20220406_zDOrSXCL8Ds2"><ix:nonNumeric contextRef="From2022-04-06to2022-04-06" name="dei:EntityAddressAddressLine1">11 Commerce Drive</ix:nonNumeric></span>, <span id="xdx_905_edei--EntityAddressAddressLine2_c20220406__20220406_zRVIHGPYvVzg"><ix:nonNumeric contextRef="From2022-04-06to2022-04-06" name="dei:EntityAddressAddressLine2">1st Floor</ix:nonNumeric></span>, <span id="xdx_903_edei--EntityAddressCityOrTown_c20220406__20220406_zMfrTDEDO2dc"><ix:nonNumeric contextRef="From2022-04-06to2022-04-06" name="dei:EntityAddressCityOrTown">Cranford</ix:nonNumeric></span>, <span id="xdx_902_edei--EntityAddressStateOrProvince_c20220406__20220406_zI465vu5b7Uf"><ix:nonNumeric contextRef="From2022-04-06to2022-04-06" name="dei:EntityAddressStateOrProvince">NJ</ix:nonNumeric></span> <span id="xdx_90A_edei--EntityAddressPostalZipCode_c20220406__20220406_z0QHhoqnZQMk"><ix:nonNumeric contextRef="From2022-04-06to2022-04-06" name="dei:EntityAddressPostalZipCode">07016</ix:nonNumeric></span></td>
    <td style="width: 30%">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: center">(Address of principal executive offices) (Zip Code)</td>
    <td>&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">Registrant's telephone number, including area code
<span style="text-decoration: underline">(<span id="xdx_901_edei--CityAreaCode_c20220406__20220406_zMOBdlqsxFvk"><ix:nonNumeric contextRef="From2022-04-06to2022-04-06" name="dei:CityAreaCode">908</ix:nonNumeric></span>) <span id="xdx_907_edei--LocalPhoneNumber_c20220406__20220406_zCyfWeQj98g5"><ix:nonNumeric contextRef="From2022-04-06to2022-04-06" name="dei:LocalPhoneNumber">967-6677</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">__________________</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: center; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_edei--WrittenCommunications_c20220406__20220406_zgHvqpp801oe"><ix:nonNumeric contextRef="From2022-04-06to2022-04-06" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span> </span></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 95%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_edei--SolicitingMaterial_c20220406__20220406_zXLsApeHelz6"><ix:nonNumeric contextRef="From2022-04-06to2022-04-06" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span> </span></td>
    <td>&#160;</td>
    <td>Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_edei--PreCommencementTenderOffer_c20220406__20220406_zYRuPFNCKC13"><ix:nonNumeric contextRef="From2022-04-06to2022-04-06" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span> </span></td>
    <td>&#160;</td>
    <td>Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_edei--PreCommencementIssuerTenderOffer_c20220406__20220406_zkg6exmI6nIk"><ix:nonNumeric contextRef="From2022-04-06to2022-04-06" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span> </span></td>
    <td>&#160;</td>
    <td>Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">Securities registered pursuant to Section 12(b) of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1pt solid; width: 33%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;Title of each class</p></td>
    <td style="border-bottom: Black 1pt solid; width: 34%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;Trading Symbol(s)</p></td>
    <td style="border-bottom: Black 1pt solid; width: 33%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">Name of each exchange on which registered</p></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt"><span id="xdx_902_edei--Security12bTitle_c20220406__20220406__us-gaap--StatementClassOfStockAxis__custom--CommonStock0.001ParValueMember_zEdc33MvYSUi"><ix:nonNumeric contextRef="From2022-04-062022-04-06_custom_CommonStock0.001ParValueMember" name="dei:Security12bTitle">Common stock, $0.001 par value</ix:nonNumeric></span></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt"><span id="xdx_906_edei--TradingSymbol_c20220406__20220406__us-gaap--StatementClassOfStockAxis__custom--CommonStock0.001ParValueMember_z0E05eCO0bT8"><ix:nonNumeric contextRef="From2022-04-062022-04-06_custom_CommonStock0.001ParValueMember" name="dei:TradingSymbol">CTXR</ix:nonNumeric></span></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">The <span id="xdx_90A_edei--SecurityExchangeName_c20220406__20220406__us-gaap--StatementClassOfStockAxis__custom--CommonStock0.001ParValueMember_zRzGuSIihp0g"><ix:nonNumeric contextRef="From2022-04-062022-04-06_custom_CommonStock0.001ParValueMember" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Capital Market</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt"><span id="xdx_903_edei--Security12bTitle_c20220406__20220406__us-gaap--StatementClassOfStockAxis__custom--WarrantsToPurchaseCommonStockMember_zjXaPdDkfO4f"><ix:nonNumeric contextRef="From2022-04-062022-04-06_custom_WarrantsToPurchaseCommonStockMember" name="dei:Security12bTitle">Warrants to purchase common stock</ix:nonNumeric></span></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt"><span id="xdx_903_edei--TradingSymbol_c20220406__20220406__us-gaap--StatementClassOfStockAxis__custom--WarrantsToPurchaseCommonStockMember_zeznd5zYxr7b"><ix:nonNumeric contextRef="From2022-04-062022-04-06_custom_WarrantsToPurchaseCommonStockMember" name="dei:TradingSymbol">CTXRW</ix:nonNumeric></span></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">The <span id="xdx_90F_edei--SecurityExchangeName_c20220406__20220406__us-gaap--StatementClassOfStockAxis__custom--WarrantsToPurchaseCommonStockMember_zVtqu39faVce"><ix:nonNumeric contextRef="From2022-04-062022-04-06_custom_WarrantsToPurchaseCommonStockMember" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Capital Market</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">Emerging growth company <span id="xdx_90E_edei--EntityEmergingGrowthCompany_c20220406__20220406_zLyoUAiI1Spe"><ix:nonNumeric contextRef="From2022-04-06to2022-04-06" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">If an emerging growth company, indicate by check mark
if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. &#9744;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>Item 8.01 Other Events.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">On April 6, 2022, Citius Pharmaceuticals, Inc. issued
a press release to announce its topline results from the Pivotal Phase 3 trial of I/ONTAK (E7777) for the treatment of persistent or recurrent
cutaneous T-cell lymphoma. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>Item 9.01. Financial Statements and Exhibits.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">(d) <span style="text-decoration: underline">Exhibits</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The following exhibit is filed
herewith:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 15pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; width: 7%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit</b></span></td>
    <td style="white-space: nowrap; width: 3%">&#160;</td>
    <td style="white-space: nowrap; width: 90%">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>No.</b></span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="border-bottom: black 1pt solid; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">99.1</span></td>
    <td style="white-space: nowrap"><span style="color: Black">&#160;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><a href="ea157980ex99-1_citius.htm">Press Release dated April 6, 2022.</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="white-space: nowrap; text-align: center">104</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="text-align: justify">Cover Page Interactive Data File (embedded within the XBRL document).</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">SIGNATURE</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">Pursuant to the requirements of the Securities Exchange
Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 5%">&#160;</td>
    <td style="width: 10%">&#160;</td>
    <td style="width: 50%">&#160;</td>
    <td style="width: 35%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CITIUS PHARMACEUTICALS, INC.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April 6, 2022</span></td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Myron Holubiak</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Myron Holubiak</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">President and Chief Executive Officer</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJx1j91OhDAQhZ+Ad5gQLwkW/LngTolujKwhSFZvK8xqs9Ah04LuI/mWlu4S90KbSZrJnO+cmTCMwhXdqw4ZXm+rAmrsh05ahAq3yKgbdIr84TED91f4roxlqa1vFzAnx6BjruIkbdzASydlsM1AXJ67SlMQF1lyDeU6DOZ5TnqrWtRWyQ6kbqFkGlihlbw/ONTyizT1ex+1QTaKdAZJLA7jb0hFksITTfKTeGegKPIwiPwLwhXTOMwxo7HUw12HvcsyB/S3/CqN12QvkufLTE3lyM2HNOju6kk/W2p2a+zfkJ04EanLvTkusTBgCYYjBY3HwMzcHzknriIWIiklb2Q34j8R+YlbBGcegUEyTDO0+P8AHTeHUw== -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea157980ex99-1_citius.htm
<DESCRIPTION>PRESS RELEASE DATED APRIL 5, 2022.
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0pt; text-align: right"><B>EXHIBIT 99.1</B></P>

<P STYLE="margin: 0pt; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="image_001.jpg" ALT="" STYLE="height: 66.75pt; width: 225pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: center"><B>Citius Pharmaceuticals Reports Topline Data
from the Pivotal Phase 3 Study of Cancer Immunotherapy I/ONTAK (E7777) for the Treatment of Persistent or Recurrent Cutaneous T-Cell Lymphoma
(CTCL) in Support of BLA Submission</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"><B>CRANFORD, N.J.</B>, April 6, 2022 -- Citius
Pharmaceuticals, Inc. (&quot;Citius&quot; or the &quot;Company&quot;) (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated
to the development and commercialization of first-in-class critical care products in oncology, anti-infectives in adjunct cancer care,
unique prescription products, and stem cell therapies,&nbsp;today reported topline results from the pivotal Phase 3 trial of I/ONTAK (E7777),
an engineered IL-2-diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma
(CTCL). The topline results for I/ONTAK (denileukin diftitox), a purified and more bioactive formulation of previously marketed ONTAK<SUP>&reg;</SUP>,
were consistent with the prior formulation. Moreover, no new safety signals were identified. Based on this data, Citius anticipates filing
a biologics license application (BLA) with the U.S. Food and Drug Administration (FDA) in the second half of 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify">&ldquo;We are encouraged by the results of the
study, which we believe are clinically meaningful, and are hopeful that I/ONTAK will be an important treatment option for patients with
persistent or recurrent CTCL. There is no single standard of care for this orphan disease. We believe the full body of data from this
and prior studies will support a successful reintroduction of denileukin diftitox to the market. We are eager to move forward with a BLA
submission for the treatment of CTCL later this year. This important milestone brings Citius one step closer to launching its first commercial
product next year, if approved by the FDA,&rdquo; stated Myron Holubiak, Chief Executive Officer of Citius.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify">&ldquo;The topline results demonstrated anti-tumor
activity in the treatment of persistent or recurrent CTCL, an incurable disease. Based on the topline data, I/ONTAK provided disease control
without cumulative toxicity. I/ONTAK has a unique dual mechanism of action that exerts both direct tumor cell killing and transient elimination
of immunosuppressive Tregs within the tumor microenvironment. The topline data further demonstrate that I/ONTAK has an average time to
response within one to two cycles of treatment in patients that have failed multiple prior therapies. If approved, we believe this biologic
with its observed efficacy and safety data, and which is already approved for CTCL and peripheral T-cell lymphoma (PTCL) patients in Japan,
would arm oncologists in the U.S. with an important additional treatment option for this devastating orphan disease,&rdquo; added Dr.
Myron Czuczman, Chief Medical Officer of Citius.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"><B>About I/ONTAK Pivotal Phase 3 Study 302 (E7777-G000-302)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify">Study (E7777-G000-302) is a pivotal, multicenter,
open-label, single-arm study of I/ONTAK (E7777) in subjects with persistent or recurrent CTCL (NCT01871727). All subjects were diagnosed
with Mycosis Fungoides or S&eacute;zary Syndrome, with tumors assessed as positive for expression of the CD25 subunit of the IL-2 receptor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify">The study was conducted in two parts with an
initial Lead-In Study to determine the optimal dose of I/ONTAK, followed by the Main Study. The Lead-In study was completed with 21 subjects
treated at doses of 6 to 15 &micro;g/kg/day. Final data collection for the Lead-In Study occurred in August 2015. The Protocol Steering
Committee selected a dose of 9 &mu;g/kg/day to be used for the Main Study. A total of 91 subjects with Stage I-IV CTCL were enrolled in
the Main Study. Study participants were administered 9 &mu;g/kg/day of I/ONTAK (E7777) by intravenous infusion over 60 minutes (+/-10
minutes) on 5 consecutive days per cycle every 21 days.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify">A total of 71 subjects with Stage I-III persistent
or recurrent CTCL from the Lead-In and Main Studies were assessed for efficacy with 69 subjects included in the Primary Efficacy Analysis
Set. Study 302 was completed in December 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"><B>Summary of Topline Efficacy and Safety Data</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify">The primary outcome measure of Study 302 is
the Objective Response Rate (ORR) based on the Global Response Score (GRS) (Olsen, JCO 2011). ORR is defined as the proportion of subjects
with a significant reduction in tumor size that can be classified as achieving either a partial response (PR) or a complete response (CR).</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">According to the trial protocol, the treatment
would be considered efficacious and demonstrate clinical benefit if the lower limit of the 2-sided 95% exact confidence interval (CI)
of the observed ORR exceeds 25.0%, as determined by the Independent Review Committee (IRC); </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In this study, the IRC determined the study achieved
an ORR of 36.2%, 95% confidence interval (25.0%, 48.7%) (25 patients out of 69); </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">An Investigator Efficacy Analysis determined
that the study achieved an ORR of 42.3%, 95% confidence interval (30.6%, 54.6%) (30 patients out of 71); </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The FDA recently provided additional written
comments indicating that their efficacy evaluation will be based on study results showing the lower limit of a 95% confidence interval
to exceed a <U>clinically relevant response rate</U> (determined during BLA review) which may be supported with data from from the prior
ONTAK study that led to ONTAK&rsquo;s intial approval. In our trial ORR will need to be supported by adequate magnitude of duration of
response and an acceptable risk/benefit ratio;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Overall rates of adverse events and serious adverse
events were consistent with published data of previously approved ONTAK. Most common adverse events included: nausea, fatigue, increased
alanine aminotransferase, chills and peripheral oedema. No new safety concerns were identified. </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify">The study evaluated additional secondary and
exploratory endpoints that include progression free survival, duration of response, time to response, skin response, duration of skin
response, time to skin response, ORR (Prince, JCO 2010) and safety.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify">These results reflect preliminary topline data
and are subject to further analysis. These data as well as full detailed results will be presented at upcoming scientific conferences
and submitted for publication.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"><B>Selected Preliminary Efficacy Data Table</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 39%; border-top: #666666 1pt solid; border-bottom: #666666 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 33%; border-top: #666666 1pt solid; border-bottom: #666666 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: center"><B>Independent (IRC) Stage I-III</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: center"><B>Primary Efficacy Analysis Set<SUP>1</SUP></B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: center"><B>(n=69*)</B></P></TD>
    <TD STYLE="width: 28%; border-top: #666666 1pt solid; border-bottom: #666666 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: center"><B>Investigator Stage I-III</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: center"><B>Efficacy Analysis Set<SUP>2</SUP></B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: center"><B>(n=71)</B></P></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #D9D9D9">
    <TD STYLE="border-bottom: #666666 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Objective Response Rate (ORR)<BR>
(Complete Response + Partial Response), n (%)</B></FONT></TD>
    <TD STYLE="border-bottom: #666666 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">25 (36.2)</FONT></TD>
    <TD STYLE="border-bottom: #666666 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">30 (42.3)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: #666666 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">95% CI</FONT></TD>
    <TD STYLE="border-bottom: #666666 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">(25.0, 48.7)</FONT></TD>
    <TD STYLE="border-bottom: #666666 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">(30.6, 54.6)</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #D9D9D9">
    <TD STYLE="border-bottom: #666666 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Duration of Response (months)</B></FONT></TD>
    <TD STYLE="border-bottom: #666666 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: #666666 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: #666666 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Subjects with Objective Response (n) </FONT></TD>
    <TD STYLE="border-bottom: #666666 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">25</FONT></TD>
    <TD STYLE="border-bottom: #666666 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">30</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: #666666 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Median observed DOR (months)</FONT></TD>
    <TD STYLE="border-bottom: #666666 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.5</FONT></TD>
    <TD STYLE="border-bottom: #666666 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.7</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: #666666 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Range (Min, Max)</FONT></TD>
    <TD STYLE="border-bottom: #666666 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3.0+, 23.5+)</FONT></TD>
    <TD STYLE="border-bottom: #666666 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">(0.7+, 26.1+)</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #D9D9D9">
    <TD STYLE="border-bottom: #666666 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Time to Response (months)</B></FONT></TD>
    <TD STYLE="border-bottom: #666666 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: #666666 1pt solid; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: #666666 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Subjects with Objective Response (n)</FONT></TD>
    <TD STYLE="border-bottom: #666666 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">25</FONT></TD>
    <TD STYLE="border-bottom: #666666 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">30</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: #666666 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Median</FONT></TD>
    <TD STYLE="border-bottom: #666666 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.41</FONT></TD>
    <TD STYLE="border-bottom: #666666 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.41</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #D9D9D9">
    <TD STYLE="border-bottom: #666666 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Clinical Benefit Rate, n (%)<BR>
(CR + PR + Durable Stable Disease) </B></FONT></TD>
    <TD STYLE="border-bottom: #666666 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>34 (49.3)</B></FONT></TD>
    <TD STYLE="border-bottom: #666666 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>38 (53.5)</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 6pt; border-bottom: #666666 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">95% CI</FONT></TD>
    <TD STYLE="padding-bottom: 6pt; border-bottom: #666666 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(37.0, 61.6)</FONT></TD>
    <TD STYLE="padding-bottom: 6pt; border-bottom: #666666 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(41.3, 65.5)</FONT></TD></TR>
  </TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">1.</TD><TD STYLE="text-align: justify">Independent Review Committee assessment of the Primary Efficacy Analysis Set which included 69 Stage I-III
CTCL subjects from the Lead-In Study and the Main Study who received a dose of 9 ug/kg/day of study drug. *Two subjects included in the
Investigator Efficacy Analysis Set were considered by the IRC to have Stage IV CTCL and excluded from the Primary Efficacy Analysis Set.
This dataset matches the patient population used for the ONTAK indication.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">2.</TD><TD STYLE="text-align: justify">Investigator Efficacy Analysis Set: All subjects considered by the Investigators to have Stage I-III CTCL
who received study drug at 9 &mu;g/kg dose in Lead-In and Main Study (n=71)</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"><B>About I/ONTAK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify">I/ONTAK is a recombinant fusion protein that
combines the interleukin-2 (IL-2) receptor binding domain with diphtheria toxin fragments. The agent specifically binds to IL-2 receptors
on the cell surface, causing diphtheria toxin fragments that have entered cells to inhibit protein synthesis. I/ONTAK, a purified version
of denileukin diftitox, is a reformulation of previously FDA-approved oncology treatment ONTAK. ONTAK was marketed in the U.S. from 1999
to 2014, when it was voluntarily withdrawn from the market. Manufacturing improvements resulted in a new formulation, which maintains
the same amino acid sequence but features improved purity and bioactivity. The new formulation received regulatory approval in Japan for
the treatment of CTCL and PTCL. In 2011 and 2013, the FDA granted orphan drug designation (ODD) to I/ONTAK for the treatment of PTCL and
CTCL, respectively, making it potentially eligible for seven years of market exclusivity post-approval for each indication.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"><B>About Cutaneous T-cell Lymphoma</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify">Cutaneous T-cell lymphoma is a type of cutaneous
non-Hodgkin lymphoma (NHL) that comes in a variety of forms and is the most common type of cutaneous lymphoma. In CTCL, T-cells, a type
of lymphocyte that plays a role in the immune system, become cancerous and develop into skin lesions, leading to a decrease in the quality
of life of patients with this disease due to severe pain and pruritus. Mycosis Fungoides (MF) and S&eacute;zary Syndrome (SS) comprise
the majority of CTCL cases. Depending on the type of CTCL, the disease may progress slowly and can take anywhere from several years to
upwards of ten to potentially reach tumor stage. However, once the disease reaches this stage, the cancer is highly malignant can spread
to the lymph nodes and internal organs, resulting in a poor prognosis. Given the duration of the disease, patients typically cycle through
multiple systemic agents to control disease progression. CTCL affects men twice as often as women and is typically first diagnosed in
patients between the ages of 50 and 60 years of age. Other than allogeneic stem cell transplantation, for which only a small fraction
of patients qualify, there is currently no curative therapy for advanced CTCL. Approximately 3,000 new cases are reported in the United
States every year, with an estimated 30,000 - 40,000 individuals living with the disease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"><B>About Citius Pharmaceuticals, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify">Citius is a late-stage biopharmaceutical company
dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives
in adjunct cancer care, unique prescription products, and stem cell therapies. The Company has two late-stage product candidates, Mino-Lok,
an antibiotic lock solution for the treatment of patients with catheter-related bloodstream infections (CRBSIs), which is currently enrolling
patients in a Phase 3 Pivotal superiority trial, and I/ONTAK (E7777), a novel IL-2R immunotherapy for an initial indication in cutaneous
T-cell lymphoma (CTCL), which has completed enrollment in its Pivotal Phase 3 trial. &nbsp;Mino-Lok<SUP>&nbsp;</SUP>was granted Fast Track
designation by the U.S. Food and Drug Administration (FDA). I/ONTAK has received orphan drug designation by the FDA for the treatment
of CTCL and peripheral T-cell lymphoma (PTCL). Through its subsidiary, NoveCite, Inc., Citius is developing a novel proprietary mesenchymal
stem cell treatment derived from induced pluripotent stem cells (iPSCs) for acute respiratory conditions, with a near-term focus on acute
respiratory distress syndrome (ARDS) associated with COVID-19.&nbsp; For more information, please visit www.citiuspharma.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt"><B></B></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt"><B>Safe Harbor</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">This press release may contain &quot;forward-looking
statements&quot; within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.
Such statements are made based on our expectations and beliefs concerning future events impacting Citius. You can identify these statements
by the fact that they use words such as &quot;believe,&quot; &quot;anticipate,&quot; &quot;estimate,&quot; &quot;expect,&quot; &quot;plan,&quot;
&quot;should,&quot; and &quot;may&quot; and other words and terms of similar meaning or use of future dates. Forward-looking statements
are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating
results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated
are: risks associated with preparing and submitting and receiving approval for our planned biologics license application for I/ONTAK;
our ability to commercialize our products if approved by the FDA; the estimated markets for our product candidates and the acceptance
thereof by any market; the ability of our product candidates to impact the quality of life of our target patient populations; our dependence
on third-party suppliers; our ability to successfully undertake and complete clinical trials and the results from those trials for our
product candidates; risks relating to the results of research and development activities, including those from existing and new pipeline
assets; uncertainties relating to preclinical and clinical testing; our need for substantial additional funds; the early stage of products
under development; market and other conditions; our ability to attract, integrate, and retain key personnel; risks related to our growth
strategy; patent and intellectual property matters; our ability to obtain, perform under and maintain financing and strategic agreements
and relationships; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely
basis; our ability to procure cGMP commercial-scale supply; government regulation; competition; as well as other risks described in our
SEC filings. These risks have been and may be further impacted by Covid-19. Accordingly, these forward-looking statements do not constitute
guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding
our business are described in detail in our Securities and Exchange Commission (&ldquo;SEC&rdquo;) filings which are available on the
SEC&rsquo;s website at www.sec.gov, including in our Annual Report on Form 10-K for the year ended September 30, 2021, filed with the
SEC on December 15, 2021 and updated by our subsequent filings with the SEC. These forward-looking statements speak only as of the date
hereof, and we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements
contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement
is based, except as required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify"><B>Investor Relations for Citius Pharmaceuticals:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Ilanit Allen</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Vice President, Investor Relations and Corporate Communications</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">T: 908-967-6677 x113</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">E: ir@citiuspharma.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><B></B></P>

<!-- Field: Page; Sequence: 5; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !9 2P# 2(  A$! Q$!_\0
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MJY&2 %.<''(KC-?\?>*;7XT/I4&M7"6"ZI% +<;=NPLH(QCT)KZ/KY,\3_\
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M-X07[1X_T\VB[4-UO5<=$&2?TK722::V.?6FXM/<Z?XA^)M:TOQ6]K8ZC-!
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M2T_6O%^M7AM['4;Z:?:7*)-MX&.>H%>U:Y_R -2_Z]9?_0#7DOPL_P"1N?\
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MAR31+O4ITGCGL+E8VM)T8$2IR0>/8CZUS?Q5^$1\7S_VUHKQ0ZN%"S1R'"7
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
6**** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>ctxr-20220406.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.13a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 9a05s7xRiXgen8uMYHRcOaSHuaP9xJBziYlBsG1zHRlKHyYuyDF0HStjDXFGkRQA -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:CTXR="http://citiuspharmaceuticals.com/20220406" elementFormDefault="qualified" targetNamespace="http://citiuspharmaceuticals.com/20220406">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://citiuspharmaceuticals.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="ctxr-20220406_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="ctxr-20220406_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="ctxr-20220406_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" />
    <import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
    <import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" />
    <element id="CTXR_CommonStock0.001ParValueMember" name="CommonStock0.001ParValueMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CTXR_WarrantsToPurchaseCommonStockMember" name="WarrantsToPurchaseCommonStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>5
<FILENAME>ctxr-20220406_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.13a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://citiuspharmaceuticals.com/role/Cover" xlink:href="ctxr-20220406.xsd#Cover" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://citiuspharmaceuticals.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="ctxr-20220406.xsd#CTXR_CommonStock0.001ParValueMember" xlink:label="loc_CTXRCommonStock0.001ParValueMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_CTXRCommonStock0.001ParValueMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="ctxr-20220406.xsd#CTXR_WarrantsToPurchaseCommonStockMember" xlink:label="loc_CTXRWarrantsToPurchaseCommonStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_CTXRWarrantsToPurchaseCommonStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentType_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentFlag_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentDescription_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentRegistrationStatement_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAnnualReport_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentQuarterlyReport_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentTransitionReport_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyReport_40" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate_40" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodStartDate_40" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodEndDate_40" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus_40" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalYearFocus_40" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate_40" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFileNumber_40" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityRegistrantName_40" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCentralIndexKey_40" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPrimarySicNumber_40" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber_40" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode_40" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine1_40" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine2_40" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine3_40" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCityOrTown_40" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressStateOrProvince_40" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCountry_40" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressPostalZipCode_40" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCountryRegion_40" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCityAreaCode_40" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiLocalPhoneNumber_40" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="loc_deiExtension_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiExtension_40" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiWrittenCommunications_40" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSolicitingMaterial_40" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementTenderOffer_40" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer_40" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12bTitle_40" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiNoTradingSymbolFlag_40" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiTradingSymbol_40" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityExchangeName_40" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12gTitle_40" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityReportingObligation_40" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAnnualInformationForm_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer_40" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityVoluntaryFilers_40" xlink:type="arc" order="44" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCurrentReportingStatus_40" xlink:type="arc" order="45" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent_40" xlink:type="arc" order="46" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFilerCategory_40" xlink:type="arc" order="47" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntitySmallBusiness_40" xlink:type="arc" order="48" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany_40" xlink:type="arc" order="49" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityExTransitionPeriod_40" xlink:type="arc" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAccountingStandard_40" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber_40" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityShellCompany_40" xlink:type="arc" order="53" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPublicFloat_40" xlink:type="arc" order="54" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent_40" xlink:type="arc" order="55" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding_40" xlink:type="arc" order="56" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock_40" xlink:type="arc" order="57" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>ctxr-20220406_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.13a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="ctxr-20220406.xsd#CTXR_CommonStock0.001ParValueMember" xlink:label="CTXR_CommonStock0.001ParValueMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CTXR_CommonStock0.001ParValueMember" xlink:to="CTXR_CommonStock0.001ParValueMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CTXR_CommonStock0.001ParValueMember_lbl" xml:lang="en-US">Common stock, $0.001 par value</link:label>
      <link:loc xlink:type="locator" xlink:href="ctxr-20220406.xsd#CTXR_WarrantsToPurchaseCommonStockMember" xlink:label="CTXR_WarrantsToPurchaseCommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CTXR_WarrantsToPurchaseCommonStockMember" xlink:to="CTXR_WarrantsToPurchaseCommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CTXR_WarrantsToPurchaseCommonStockMember_lbl" xml:lang="en-US">Warrants to purchase common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>ctxr-20220406_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.13a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://citiuspharmaceuticals.com/role/Cover" xlink:href="ctxr-20220406.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://citiuspharmaceuticals.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="ctxr-20220406.xsd#CTXR_CommonStock0.001ParValueMember" xlink:label="loc_CTXRCommonStock0.001ParValueMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_CTXRCommonStock0.001ParValueMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="ctxr-20220406.xsd#CTXR_WarrantsToPurchaseCommonStockMember" xlink:label="loc_CTXRWarrantsToPurchaseCommonStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_CTXRWarrantsToPurchaseCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140709785788776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Apr. 06, 2022</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Apr.  06,  2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">333-206903<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Citius Pharmaceuticals, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001506251<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">27-3425913<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">11 Commerce Drive<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">1st Floor<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cranford<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07016<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">908<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">967-6677<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=CTXR_CommonStock0.001ParValueMember', window );">Common stock, $0.001 par value</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, $0.001 par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CTXR<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=CTXR_WarrantsToPurchaseCommonStockMember', window );">Warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Warrants to purchase common stock<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CTXRW<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=CTXR_CommonStock0.001ParValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=CTXR_CommonStock0.001ParValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=CTXR_WarrantsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=CTXR_WarrantsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>ea157980-8k_citius_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:CTXR="http://citiuspharmaceuticals.com/20220406"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ctxr-20220406.xsd" xlink:type="simple"/>
    <context id="From2022-04-06to2022-04-06">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506251</identifier>
        </entity>
        <period>
            <startDate>2022-04-06</startDate>
            <endDate>2022-04-06</endDate>
        </period>
    </context>
    <context id="From2022-04-062022-04-06_custom_CommonStock0.001ParValueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CTXR:CommonStock0.001ParValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-06</startDate>
            <endDate>2022-04-06</endDate>
        </period>
    </context>
    <context id="From2022-04-062022-04-06_custom_WarrantsToPurchaseCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506251</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CTXR:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-06</startDate>
            <endDate>2022-04-06</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2022-04-06to2022-04-06">0001506251</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2022-04-06to2022-04-06">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2022-04-06to2022-04-06">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2022-04-06to2022-04-06">2022-04-06</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2022-04-06to2022-04-06">Citius Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2022-04-06to2022-04-06">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2022-04-06to2022-04-06">333-206903</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2022-04-06to2022-04-06">27-3425913</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2022-04-06to2022-04-06">11 Commerce Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2022-04-06to2022-04-06">1st Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2022-04-06to2022-04-06">Cranford</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2022-04-06to2022-04-06">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2022-04-06to2022-04-06">07016</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2022-04-06to2022-04-06">908</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2022-04-06to2022-04-06">967-6677</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="From2022-04-06to2022-04-06">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2022-04-06to2022-04-06">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2022-04-06to2022-04-06">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2022-04-06to2022-04-06">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="From2022-04-062022-04-06_custom_CommonStock0.001ParValueMember">Common stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2022-04-062022-04-06_custom_CommonStock0.001ParValueMember">CTXR</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2022-04-062022-04-06_custom_CommonStock0.001ParValueMember">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="From2022-04-062022-04-06_custom_WarrantsToPurchaseCommonStockMember">Warrants to purchase common stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2022-04-062022-04-06_custom_WarrantsToPurchaseCommonStockMember">CTXRW</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2022-04-062022-04-06_custom_WarrantsToPurchaseCommonStockMember">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="From2022-04-06to2022-04-06">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MCVG.D4*NU"P>-8?20$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^
MKSI,<4)I2$LS#O#-TG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE
M?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @
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M 5!+ 0(4 Q0    ( &-!AE0'04UB@0   +$    0              "  0
M  !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ 8T&&5-B?LR?N    *P(
M !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%
M  @ 8T&&5)E<G",0!@  G"<  !,              ( !S $  'AL+W1H96UE
M+W1H96UE,2YX;6Q02P$"% ,4    " !C08947?S)4GL$   /$P  &
M        @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%
M  @ 8T&&5.#T.HFJ @  , P   T              ( !O@P  'AL+W-T>6QE
M<RYX;6Q02P$"% ,4    " !C0894EXJ[',     3 @  "P
M@ &3#P  7W)E;',O+G)E;'-02P$"% ,4    " !C0894JL0B%C,!   B @
M#P              @ %\$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @
M8T&&5"0>FZ*M    ^ $  !H              ( !W!$  'AL+U]R96QS+W=O
M<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ 8T&&5&60>9(9 0  SP,  !,
M             ( !P1(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D
,"0 ^ @  "Q0

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>3</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>2</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="ea157980-8k_citius.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://citiuspharmaceuticals.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="ea157980-8k_citius.htm">ea157980-8k_citius.htm</File>
    <File>ctxr-20220406.xsd</File>
    <File>ctxr-20220406_def.xml</File>
    <File>ctxr-20220406_lab.xml</File>
    <File>ctxr-20220406_pre.xml</File>
    <File>ea157980ex99-1_citius.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="26">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "ea157980-8k_citius.htm": {
   "axisCustom": 0,
   "axisStandard": 1,
   "contextCount": 3,
   "dts": {
    "definitionLink": {
     "local": [
      "ctxr-20220406_def.xml"
     ]
    },
    "inline": {
     "local": [
      "ea157980-8k_citius.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ctxr-20220406_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ctxr-20220406_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "ctxr-20220406.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 65,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021q4": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 2,
   "memberStandard": 0,
   "nsprefix": "CTXR",
   "nsuri": "http://citiuspharmaceuticals.com/20220406",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "ea157980-8k_citius.htm",
      "contextRef": "From2022-04-06to2022-04-06",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://citiuspharmaceuticals.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "ea157980-8k_citius.htm",
      "contextRef": "From2022-04-06to2022-04-06",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 2,
   "tag": {
    "CTXR_CommonStock0.001ParValueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, $0.001 par value"
       }
      }
     },
     "localname": "CommonStock0.001ParValueMember",
     "nsuri": "http://citiuspharmaceuticals.com/20220406",
     "presentation": [
      "http://citiuspharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "CTXR_WarrantsToPurchaseCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants to purchase common stock"
       }
      }
     },
     "localname": "WarrantsToPurchaseCommonStockMember",
     "nsuri": "http://citiuspharmaceuticals.com/20220406",
     "presentation": [
      "http://citiuspharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://citiuspharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://citiuspharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://citiuspharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://citiuspharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://citiuspharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://citiuspharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://citiuspharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://citiuspharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://citiuspharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://citiuspharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://citiuspharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://citiuspharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://citiuspharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://citiuspharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://citiuspharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://citiuspharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://citiuspharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://citiuspharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://citiuspharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://citiuspharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://citiuspharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://citiuspharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://citiuspharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://citiuspharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://citiuspharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://citiuspharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://citiuspharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://citiuspharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://citiuspharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://citiuspharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://citiuspharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://citiuspharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://citiuspharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://citiuspharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://citiuspharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://citiuspharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://citiuspharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://citiuspharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://citiuspharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://citiuspharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://citiuspharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://citiuspharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://citiuspharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://citiuspharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://citiuspharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://citiuspharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://citiuspharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://citiuspharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://citiuspharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://citiuspharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://citiuspharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://citiuspharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://citiuspharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://citiuspharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://citiuspharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://citiuspharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://citiuspharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://citiuspharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [],
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://citiuspharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://citiuspharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://citiuspharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://citiuspharmaceuticals.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r10": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r11": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r12": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r19": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r9": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001213900-22-018307-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-22-018307-xbrl.zip
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MSU&AIF?FHJBA3"N_0'(>*1#*[A*AC59S..AAJF1ZQG20@VY_D/3%/R:G[\S
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M/_0.*JB+O]>?)>?-#_-W;_29_P-02P,$%     @ 8T&&5%\MHBWG"P  I)
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ME&M14^P!C2E+XBC.8KKZ("Y.>8QM-;.)7$$!&RR),!5!X #:,K+)5$)4*CV
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M]:CQ[$6O0M!6^6"_+;YQO]R_;K![_@%02P,$%     @ 8T&&5! :'[6M$@
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M3U[-Y-RA 8(!H=Q1!41#6!_45<X==2&37IDLA^4)/D%)GI4OJ+PPI_*7FDY
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MM2:[K^>=:E&Z2&''R)D@=RO2!E0F]TXEQ3S';XS[LJD?V9]^G\8]2O+6/S?
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MG@)Q*P':-"4#7L!5WD6E:'QX*QM2EV-3J,;EY3J?PDTM;;,7I_1KP@[!F^P
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M F;*H 0ZWN$4M^"+KMBM,,0OE^ <['P-ZM5A1C.:DP.*V]P]\@']):&!0>=
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MVT7I):3_#U!+ 0(4 Q0    ( &-!AE1;B6K#V@,  .4.   1
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;<RYH=&U02P4&      8 !@"3 0  /5$

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
